<table id="t6" width="100%" xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<caption>Table 6: Established and Other Potentially Significant Drug Interactions: Alterations in Dose or Regimen May be Recommended Based on Drug Interaction Studies or Predicted Interaction</caption>
<col align="left" valign="top" width="25%"></col>
<col align="left" valign="top" width="20%"></col>
<col align="left" valign="top" width="55%"></col>
<thead>
<tr>
<th stylecode="Lrule Rrule">Concomitant Drug<br/>Class<br/>Drug Name</th>
<th stylecode="Lrule Rrule">Effect on Concentration of Simeprevir or Concomitant Drug</th>
<th stylecode="Lrule Rrule">Clinical Comment</th>
</tr>
</thead>
<tfoot>
<tr>
<td align="left" colspan="3">The direction of the arrow (↑ = increase, ↓ = decrease, ↔ = no change) indicates the direction of the change in PK.</td>
</tr>
</tfoot>
<tbody>
<tr stylecode="Botrule">
<td colspan="3" stylecode="Lrule Rrule Toprule">
<content stylecode="bold">Antiarrhythmics</content>
</td>
</tr>
<tr>
<td stylecode="Lrule Rrule Toprule">Amiodarone</td>
<td stylecode="Lrule Rrule Toprule Botrule">Effect on amiodarone, simeprevir, and sofosbuvir concentrations unknown</td>
<td stylecode="Lrule Rrule Toprule Botrule">Co-administration of amiodarone with OLYSIO in combination with sofosbuvir is not recommended because it may result in serious symptomatic bradycardia. The mechanism of this effect is unknown. If co-administration is required, cardiac monitoring is recommended <content stylecode="italics">[see <linkhtml href="#S5.1">Warnings and Precautions (5.1)</linkhtml>, <linkhtml href="#S6.2">Adverse Reactions (6.2)</linkhtml>].</content>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule"></td>
<td stylecode="Lrule Rrule Toprule">↑ amiodarone</td>
<td stylecode="Lrule Rrule Toprule">Caution is warranted and therapeutic drug monitoring of amiodarone, if available, is recommended for concomitant use of amiodarone with an OLYSIO-containing regimen that does not contain sofosbuvir. <br/>Concomitant use of OLYSIO with amiodarone when given orally may result in mild increases in amiodarone concentrations due to intestinal CYP3A4 inhibition by simeprevir.</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule Toprule">Digoxin<footnote id="ft6.1">These interactions have been studied in healthy adults with the recommended dose of 150 mg simeprevir once daily unless otherwise noted <content stylecode="italics">[see <linkhtml href="#S12.3">Clinical Pharmacology (12.3)</linkhtml>, <linkhtml href="#t7">Tables 7</linkhtml>
</content> and <content stylecode="italics">
<linkhtml href="#t8">8</linkhtml>]</content>.</footnote>
</td>
<td stylecode="Lrule Rrule Toprule">↑ digoxin</td>
<td stylecode="Lrule Rrule Toprule">Concomitant use of OLYSIO with digoxin resulted in increased concentrations of digoxin due to inhibition of P-gp by simeprevir. Routine therapeutic drug monitoring of digoxin concentrations is acceptable.</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule Toprule">
<content stylecode="italics">Oral administration</content>
<br/>Disopyramide<br/>Flecainide<br/>Mexiletine<br/>Propafenone<br/>Quinidine</td>
<td stylecode="Lrule Rrule Toprule">↑ antiarrhythmics</td>
<td stylecode="Lrule Rrule Toprule">Concomitant use of OLYSIO with these antiarrhythmics when given orally may result in mild increases in concentrations of these antiarrhythmics due to intestinal CYP3A4 inhibition by simeprevir. Therapeutic drug monitoring for these antiarrhythmics, if available, is recommended when co-administered with OLYSIO.</td>
</tr>
<tr stylecode="Botrule">
<td colspan="3" stylecode="Lrule Rrule Toprule">
<content stylecode="bold">Anticonvulsants</content>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule Toprule">Carbamazepine<br/>Oxcarbazepine<br/>Phenobarbital<br/>Phenytoin</td>
<td stylecode="Lrule Rrule Toprule">↓ simeprevir</td>
<td stylecode="Lrule Rrule Toprule">Concomitant use of OLYSIO with carbamazepine, oxcarbazepine, phenobarbital or phenytoin may result in significantly decreased plasma concentrations of simeprevir due to strong CYP3A induction by these anticonvulsants. This may result in loss of therapeutic effect of OLYSIO. Co-administration of OLYSIO with these anticonvulsants is not recommended.</td>
</tr>
<tr stylecode="Botrule">
<td colspan="3" stylecode="Lrule Rrule Toprule">
<content stylecode="bold">Anti-infectives</content>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule Toprule">
<content stylecode="bold">Antibiotics (systemic administration):</content>
<br/>Erythromycin<footnoteref idref="ft6.1"></footnoteref>
</td>
<td stylecode="Lrule Rrule Toprule">↑ simeprevir<br/>↑ erythromycin</td>
<td stylecode="Lrule Rrule Toprule">Concomitant use of OLYSIO with erythromycin resulted in significantly increased plasma concentrations of both erythromycin and simeprevir due to inhibition of CYP3A and P-gp by both erythromycin and simeprevir. Co-administration of OLYSIO with systemic erythromycin is not recommended.</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule Toprule">
<content stylecode="bold">Antibiotics (systemic administration):</content>
<br/>Clarithromycin<br/>Telithromycin</td>
<td stylecode="Lrule Rrule Toprule">↑ simeprevir</td>
<td stylecode="Lrule Rrule Toprule">Concomitant use of OLYSIO with clarithromycin or telithromycin may result in increased plasma concentrations of simeprevir due to CYP3A inhibition by these antibiotics. Co-administration of OLYSIO with systemic clarithromycin or telithromycin is not recommended.</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule Toprule">
<content stylecode="bold">Antifungals (systemic administration):</content>
<br/>Itraconazole<br/>Ketoconazole<br/>Posaconazole</td>
<td stylecode="Lrule Rrule Toprule">↑ simeprevir</td>
<td stylecode="Lrule Rrule Toprule">Concomitant use of OLYSIO with systemic itraconazole, ketoconazole or posaconazole may result in significantly increased plasma concentrations of simeprevir due to strong CYP3A inhibition by these antifungals. Co-administration of OLYSIO with systemic itraconazole, ketoconazole or posaconazole is not recommended.</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule Toprule">
<content stylecode="bold">Antifungals (systemic administration):</content>
<br/>Fluconazole<br/>Voriconazole</td>
<td stylecode="Lrule Rrule Toprule">↑ simeprevir</td>
<td stylecode="Lrule Rrule Toprule">Concomitant use of OLYSIO with systemic fluconazole or voriconazole may result in increased plasma concentrations of simeprevir due to mild to moderate CYP3A inhibition by these antifungals. Co-administration of OLYSIO with systemic fluconazole or voriconazole is not recommended.</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule Toprule">
<content stylecode="bold">Antimycobacterials:</content>
<br/>Rifampin<footnoteref idref="ft6.1"></footnoteref>
<footnote>The dose of OLYSIO in this interaction study was 200 mg once daily both when given alone and when co-administered with rifampin 600 mg once daily.</footnote>
<br/>Rifabutin<br/>Rifapentine</td>
<td stylecode="Lrule Rrule Toprule">↓ simeprevir<br/>↔ rifampin, rifabutin, rifapentine</td>
<td stylecode="Lrule Rrule Toprule">Concomitant use of OLYSIO with rifampin, rifabutin or rifapentine may result in significantly decreased plasma concentrations of simeprevir due to CYP3A4 induction by these antimycobacterials. This may result in loss of therapeutic effect of OLYSIO. Co-administration of OLYSIO with rifampin, rifabutin or rifapentine is not recommended.</td>
</tr>
<tr stylecode="Botrule">
<td colspan="3" stylecode="Lrule Rrule Toprule">
<content stylecode="bold">Calcium Channel Blockers (oral administration)</content>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule Toprule">Amlodipine<br/>Diltiazem<br/>Felodipine<br/>Nicardipine<br/>Nifedipine<br/>Nisoldipine<br/>Verapamil</td>
<td stylecode="Lrule Rrule Toprule">↑ calcium channel blockers</td>
<td stylecode="Lrule Rrule Toprule">Concomitant use of OLYSIO with orally administered calcium channel blockers may result in increased plasma concentrations of calcium channel blockers due to intestinal CYP3A4 and/or P-gp inhibition by simeprevir. Clinical monitoring of patients is recommended when OLYSIO is co-administered with orally administered calcium channel blockers.</td>
</tr>
<tr stylecode="Botrule">
<td colspan="3" stylecode="Lrule Rrule Toprule">
<content stylecode="bold">Corticosteroids</content>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule Toprule">
<content stylecode="italics">Systemic</content>
<br/>Dexamethasone</td>
<td stylecode="Lrule Rrule Toprule">↓ simeprevir</td>
<td stylecode="Lrule Rrule Toprule">Concomitant use of OLYSIO with systemic dexamethasone may result in decreased plasma concentrations of simeprevir due to moderate induction of CYP3A4 by dexamethasone. This may result in loss of therapeutic effect of OLYSIO. Co-administration of OLYSIO with systemic dexamethasone is not recommended.</td>
</tr>
<tr stylecode="Botrule">
<td colspan="3" stylecode="Lrule Rrule Toprule">
<content stylecode="bold">Gastrointestinal Products</content>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule Toprule">
<content stylecode="bold">Propulsive:</content>
<br/>Cisapride</td>
<td stylecode="Lrule Rrule Toprule">↑ cisapride</td>
<td stylecode="Lrule Rrule Toprule">Cisapride has the potential to cause cardiac arrhythmias. Concomitant use of OLYSIO with cisapride may result in increased plasma concentrations of cisapride due to intestinal CYP3A4 inhibition by simeprevir. Co-administration of OLYSIO with cisapride is not recommended.</td>
</tr>
<tr stylecode="Botrule">
<td colspan="3" stylecode="Lrule Rrule Toprule">
<content stylecode="bold">Herbal Products</content>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule Toprule">Milk thistle<br/>(<content stylecode="italics">Silybum marianum</content>)</td>
<td stylecode="Lrule Rrule Toprule">↑ simeprevir</td>
<td stylecode="Lrule Rrule Toprule">Concomitant use of OLYSIO with milk thistle may result in increased plasma concentrations of simeprevir due to CYP3A inhibition by milk thistle. Co-administration of OLYSIO with milk thistle is not recommended.</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule Toprule">St. John's wort (<content stylecode="italics">Hypericum perforatum</content>)</td>
<td stylecode="Lrule Rrule Toprule">↓ simeprevir</td>
<td stylecode="Lrule Rrule Toprule">Concomitant use of OLYSIO with products containing St. John's wort may result in significantly decreased plasma concentrations of simeprevir due to CYP3A induction by St. John's wort. This may result in loss of therapeutic effect of OLYSIO. Co-administration of OLYSIO with products containing St. John's wort is not recommended.</td>
</tr>
<tr stylecode="Botrule">
<td colspan="3" stylecode="Lrule Rrule Toprule">
<content stylecode="bold">HIV Products</content>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule Toprule">Cobicistat-containing product (elvitegravir/cobicistat/<br/>emtricitabine/tenofovir disoproxil fumarate)</td>
<td stylecode="Lrule Rrule Toprule">↑ simeprevir</td>
<td stylecode="Lrule Rrule Toprule">Concomitant use of OLYSIO and a cobicistat-containing product (elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate) may result in significantly increased plasma concentrations of simeprevir due to strong CYP3A inhibition by cobicistat. Co-administration of OLYSIO with a cobicistat-containing product is not recommended.</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule Toprule">
<content stylecode="bold">Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs):</content>
<br/>Efavirenz<footnoteref idref="ft6.1"></footnoteref>
</td>
<td stylecode="Lrule Rrule Toprule">↓ simeprevir<br/>↔ efavirenz</td>
<td stylecode="Lrule Rrule Toprule">Concomitant use of OLYSIO with efavirenz resulted in significantly decreased plasma concentrations of simeprevir due to CYP3A induction by efavirenz. This may result in loss of therapeutic effect of OLYSIO. Co-administration of OLYSIO with efavirenz is not recommended.</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule Toprule">
<content stylecode="bold">Other NNRTIs</content>
<br/>(Delavirdine, Etravirine, Nevirapine)</td>
<td stylecode="Lrule Rrule Toprule">↑ or ↓ simeprevir</td>
<td stylecode="Lrule Rrule Toprule">Concomitant use of OLYSIO with delavirdine, etravirine or nevirapine may result in altered plasma concentrations of simeprevir due to CYP3A inhibition (delavirdine) or induction (etravirine and nevirapine) by these drugs. Co-administration of OLYSIO with delavirdine, etravirine or nevirapine is not recommended.</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule Toprule">
<content stylecode="bold">Protease Inhibitors (PIs):</content>
<br/>Darunavir/ritonavir<footnoteref idref="ft6.1"></footnoteref>
<footnote>The dose of OLYSIO in this interaction study was 50 mg when co-administered in combination with darunavir/ritonavir, compared to 150 mg in the OLYSIO alone treatment group.</footnote>
</td>
<td stylecode="Lrule Rrule Toprule">↑ simeprevir<br/>↑ darunavir</td>
<td stylecode="Lrule Rrule Toprule">Concomitant use of OLYSIO with darunavir/ritonavir resulted in increased plasma concentrations of simeprevir due to CYP3A inhibition by darunavir/ritonavir. Co-administration of darunavir/ritonavir and OLYSIO is not recommended.</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule Toprule">
<content stylecode="bold">Protease Inhibitors (PIs):</content>
<br/>Ritonavir<footnoteref idref="ft6.1"></footnoteref>
<footnote>The dose of OLYSIO in this interaction study was 200 mg once daily both when given alone and when co-administered in combination with ritonavir 100 mg given twice daily.</footnote>
</td>
<td stylecode="Lrule Rrule Toprule">↑ simeprevir</td>
<td stylecode="Lrule Rrule Toprule">Concomitant use of OLYSIO with ritonavir resulted in significantly increased plasma concentrations of simeprevir due to strong CYP3A inhibition by ritonavir. Co-administration of OLYSIO with ritonavir is not recommended.</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule Toprule">Other ritonavir-boosted or unboosted HIV PIs, e.g., Atazanavir, Fosamprenavir, Lopinavir, Indinavir, Nelfinavir, Saquinavir, Tipranavir</td>
<td stylecode="Lrule Rrule Toprule">↑ or ↓ simeprevir</td>
<td stylecode="Lrule Rrule Toprule">Concomitant use of OLYSIO with ritonavir-boosted or unboosted HIV PIs may result in altered plasma concentrations of simeprevir due to CYP3A inhibition or induction by these HIV PIs. Co-administration of OLYSIO with any HIV PI, with or without ritonavir is not recommended.</td>
</tr>
<tr stylecode="Botrule">
<td colspan="3" stylecode="Lrule Rrule Toprule">
<content stylecode="bold">HMG CO-A Reductase Inhibitors</content>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule Toprule">Rosuvastatin<footnoteref idref="ft6.1"></footnoteref>
</td>
<td stylecode="Lrule Rrule Toprule">↑ rosuvastatin</td>
<td stylecode="Lrule Rrule Toprule">Concomitant use of OLYSIO with rosuvastatin resulted in increased plasma concentrations of rosuvastatin due to inhibition of OATP1B1 by simeprevir. Initiate rosuvastatin therapy with 5 mg once daily. The rosuvastatin dose should not exceed 10 mg daily when co-administered with OLYSIO.</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule Toprule">Atorvastatin<footnoteref idref="ft6.1"></footnoteref>
</td>
<td stylecode="Lrule Rrule Toprule">↑ atorvastatin</td>
<td stylecode="Lrule Rrule Toprule">Concomitant use of OLYSIO with atorvastatin resulted in increased plasma concentrations of atorvastatin due to inhibition of OATP1B1 and/or CYP3A4 by simeprevir. Use the lowest necessary dose of atorvastatin, but do not exceed a daily dose of 40 mg when co-administering with OLYSIO.</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule Toprule">Simvastatin<footnoteref idref="ft6.1"></footnoteref>
</td>
<td stylecode="Lrule Rrule Toprule">↑ simvastatin</td>
<td stylecode="Lrule Rrule Toprule">Concomitant use of OLYSIO with simvastatin resulted in increased plasma concentrations of simvastatin due to inhibition of OATP1B1 and/or CYP3A4 by simeprevir. Titrate the simvastatin dose carefully and use the lowest necessary dose of simvastatin while monitoring for safety when co-administered with OLYSIO.</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule Toprule">Pitavastatin<br/>Pravastatin<br/>Lovastatin</td>
<td stylecode="Lrule Rrule Toprule">↑ pitavastatin, pravastatin, lovastatin</td>
<td stylecode="Lrule Rrule Toprule">Concomitant use of OLYSIO with pitavastatin, pravastatin or lovastatin has not been studied. The dose of pitavastatin, pravastatin or lovastatin should be titrated carefully and the lowest necessary dose should be used while monitoring for safety when co-administered with OLYSIO.</td>
</tr>
<tr stylecode="Botrule">
<td colspan="3" stylecode="Lrule Rrule Toprule">
<content stylecode="bold">Immunosuppressants</content>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule Toprule">Cyclosporine<footnoteref idref="ft6.1"></footnoteref>
</td>
<td stylecode="Lrule Rrule Toprule">↑ cyclosporine<br/>↑ simeprevir<footnote id="ft6.2">Studied in combination with an investigational drug and RBV in a Phase 2 trial in HCV-infected post-liver transplant patients.</footnote>
</td>
<td stylecode="Lrule Rrule Toprule">Concomitant use of OLYSIO with cyclosporine resulted in significantly increased plasma concentrations of simeprevir due to inhibition of OATP1B1, P-gp and CYP3A by cyclosporine. It is not recommended to co-administer OLYSIO with cyclosporine.</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule Toprule">Sirolimus</td>
<td stylecode="Lrule Rrule Toprule">↑ or ↓ sirolimus</td>
<td stylecode="Lrule Rrule Toprule">Concomitant use of OLYSIO and sirolimus may result in mildly increased or decreased plasma concentrations of sirolimus. Routine monitoring of blood concentrations of sirolimus is acceptable.</td>
</tr>
<tr stylecode="Botrule">
<td colspan="3" stylecode="Lrule Rrule Toprule">
<content stylecode="bold">Phosphodiesterase Type 5 (PDE-5) Inhibitors</content>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule Toprule">Sildenafil<br/>Tadalafil<br/>Vardenafil</td>
<td stylecode="Lrule Rrule Toprule">↑ PDE-5 inhibitors</td>
<td stylecode="Lrule Rrule Toprule">Concomitant use of OLYSIO with PDE-5 inhibitors may result in mild increases in concentrations of PDE-5 inhibitors due to intestinal CYP3A4 inhibition by simeprevir.<br/>No dose adjustment is required when OLYSIO is co-administered with doses of sildenafil, tadalafil or vardenafil indicated for the treatment of erectile dysfunction.<br/>Dose adjustment of the PDE-5 inhibitor may be required when OLYSIO is co-administered with sildenafil or tadalafil administered chronically at doses used for the treatment of pulmonary arterial hypertension. Consider starting with the lowest dose of the PDE-5 inhibitor and increase as needed, with clinical monitoring as appropriate.</td>
</tr>
<tr stylecode="Botrule">
<td colspan="3" stylecode="Lrule Rrule Toprule">
<content stylecode="bold">Sedatives/Anxiolytics</content>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule Toprule">Midazolam<footnoteref idref="ft6.1"></footnoteref> (oral administration)</td>
<td stylecode="Lrule Rrule Toprule">↑ midazolam</td>
<td stylecode="Lrule Rrule Toprule">Concomitant use of OLYSIO with orally administered midazolam resulted in increased plasma concentrations of midazolam due to mild inhibition of intestinal CYP3A4 by simeprevir. Caution is warranted when this drug, with a narrow therapeutic index, is co-administered with OLYSIO via the oral route.</td>
</tr>
<tr>
<td stylecode="Lrule Rrule Toprule">Triazolam (oral administration)</td>
<td stylecode="Lrule Rrule Toprule">↑ triazolam</td>
<td stylecode="Lrule Rrule Toprule">Concomitant use of OLYSIO with orally administered triazolam may result in mild increases in concentrations of triazolam due to intestinal CYP3A4 inhibition by simeprevir. Caution is warranted when this drug, with a narrow therapeutic index, is co-administered with OLYSIO via the oral route.</td>
</tr>
</tbody>
</table>